Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis

NCT02230982 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02230982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02230982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Boehringer Ingelheim
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis